Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy
Oral Oncology , 05/10/2012
Clinical Article
Huang PY et al. – High tumor excision repair cross–complementation group 1 (ERCC1) expression predicts low chemotherapy response and poor survival mainly caused by more metastasis in locoregionally advanced nasopharyngeal carcinoma (NPC) treated with cisplatin–based induction chemotherapy.



